Anti‐TNF treatment in Crohn's disease and risk of bowel resection—a population based cohort study

• DOI: 10.1111/apt.14224
• Publication Date: 2017-07-28T08:32:04Z
• Authors: M. Eberhardson; J. K. Söderling; M. Neovius; T. Cars; P. Myrelid; J. F. Ludvigsson; J. Askling; A. Ekbom; O. Olén
• Keywords: Bowel resection

TNF inhibitors (TNFi) have been shown to reduce the need for surgery in Crohn's disease, but few studies examined their effect beyond first year of treatment.To conduct a register-based observational cohort study Sweden 2006-2014 investigate risk bowel resection naïve TNFi-treated disease patients and whether on TNFi ≥12 months are less likely undergo than discontinuing treatment before 12 months.We identified all individuals with through Swedish National Patient Register 1987-2014 evaluated incidence after ever dispensation adalimumab or infliximab from 2006 up 7 years follow-up.We 1856 who had received TNFi. Among these patients, 90% retention was observed at 6 start 65% remained drug months. The cumulative rates exposed 1-7 were 7%, 13%, 17%, 20%, 23%, 25% 28%. Rates similar between survival <12 respectively (P=.27). No predictors (eg, sex, age, extension duration disease) identified.The anti-TNF is higher regular health care published RCTs. Patients sustained those discontinue earlier.